04:37:27 EST Sun 25 Feb 2018
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Z:MNK - Mallinckrodt plc Ordinary Shares - http://www.mallinckrodt.com04:37:27 EST
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNK - Z0.516.05 · 16.210.516.16+0.241.52,447.039,76713,36816.07  16.76  16.0454.90  15.2716:09:4206:5515 min RT 2¢

Recent Trades - Last 10 of 13368
Time ETExPriceChangeVolume
16:09:42Z16.160.2481
16:09:42Z16.160.2420
16:09:41Z16.160.24122
16:02:02Z16.160.24480
16:02:02Z16.160.241,058
16:02:02Z16.160.2485
16:02:02Z16.160.242,710
16:02:02Z16.160.24100
16:02:02Z16.160.24150
16:02:02Z16.160.242,105

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2018-02-23 06:55U:MNKNews ReleaseMallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing
2018-02-21 06:30U:MNKNews ReleaseMallinckrodt Earns Somerset County Planning Board Land Development Honor
2018-02-15 16:50U:MNKNews ReleaseMallinckrodt To Present At Barclays Global Healthcare Conference
2018-02-14 06:30U:MNKNews ReleaseMallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft ™C9T1 Skin Tissue
2018-02-13 09:00U:MNKNews ReleaseMallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc.
2018-02-06 17:53U:MNKNews ReleaseBoyd Gaming Set to Join S&P MidCap 400; Ring Energy, James River Group Holdings and EVERTEC to Join S&P SmallCap 600
2018-02-06 16:45U:MNKNews ReleaseMallinckrodt To Present At Raymond James 39th Annual Institutional Investors Conference
2018-02-01 09:05U:MNKNews ReleaseMark Casey Joins Mallinckrodt as General Counsel
2018-01-30 16:45U:MNKNews ReleaseFirst Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar ® Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis